Wednesday, August 2, 2017

Leukemia - Table of Contents alert Volume 31 Issue 8

If you are unable to see the message below, click here to view.


Volume 31, Issue 8 (August 2017)

In this issue
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Celebrating 30 years of Leukemia — 1987 to 2017

Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone.

Watch our anniversary video showing a brief impact overview >>>



The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders

N Maslah, B Cassinat, E Verger, J-J Kiladjian and L Velazquez

Leukemia 2017 31: 1661-1670; advance online publication, May 9, 2017; 10.1038/leu.2017.139

Abstract | Full Text

Why are hematopoietic stem cells so ‘sexy’? on a search for developmental explanation OPEN

M Z Ratajczak

Leukemia 2017 31: 1671-1677; advance online publication, May 15, 2017; 10.1038/leu.2017.148

Abstract | Full Text

A revisionist history of adult marrow stem cell biology or ‘they forgot about the discard’

P Quesenberry and L Goldberg

Leukemia 2017 31: 1678-1685; advance online publication, May 22, 2017; 10.1038/leu.2017.155

Abstract | Full Text

Original Articles



IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus

S Drennan, A D'Avola, Y Gao, C Weigel, E Chrysostomou, A J Steele, T Zenz, C Plass, P W Johnson, A P Williams, G Packham, F K Stevenson, C C Oakes and F Forconi

Leukemia 2017 31: 1686-1694; advance online publication, November 28, 2016; 10.1038/leu.2016.356

Abstract | Full Text


Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

S Mithraprabhu, T Khong, M Ramachandran, A Chow, D Klarica, L Mai, S Walsh, D Broemeling, A Marziali, M Wiggin, J Hocking, A Kalff, B Durie and A Spencer

Leukemia 2017 31: 1695-1705; advance online publication, November 30, 2016; 10.1038/leu.2016.366

Abstract | Full Text

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

I J F Hofman, M van Duin, E De Bruyne, L Fancello, G Mulligan, E Geerdens, E Garelli, C Mancini, H Lemmens, M Delforge, P Vandenberghe, I Wlodarska, A Aspesi, L Michaux, K Vanderkerken, P Sonneveld and K De Keersmaecker

Leukemia 2017 31: 1706-1714; advance online publication, December 2, 2016; 10.1038/leu.2016.370

Abstract | Full Text

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma

J R Nair, J Caserta, K Belko, T Howell, G Fetterly, C Baldino and K P Lee

Leukemia 2017 31: 1715-1726; advance online publication, December 23, 2016; 10.1038/leu.2016.379

Abstract | Full Text

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano, A Evangelista, S Spada, P Campbell, R Ria, M Salvini, M Offidani, A M Carella, P Omedé, A M Liberati, R Troia, A M Cafro, A Malfitano, A P Falcone, T Caravita, F Patriarca, A Nagler, A Spencer, R Hajek, A Palumbo and M Boccadoro

Leukemia 2017 31: 1727-1734; advance online publication, December 23, 2016; 10.1038/leu.2016.381

Abstract | Full Text

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma

M I da Silva Filho, A Försti, N Weinhold, I Meziane, C Campo, S Huhn, J Nickel, P Hoffmann, M M Nöthen, K-H Jöckel, S Landi, J S Mitchell, D Johnson, G J Morgan, R Houlston, H Goldschmidt, A Jauch, P Milani, G Merlini, D Rowcieno, P Hawkins, U Hegenbart, G Palladini, A Wechalekar, S O Schönland and K Hemminki

Leukemia 2017 31: 1735-1742; advance online publication, December 27, 2016; 10.1038/leu.2016.387

Abstract | Full Text

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo OPEN

S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson and M Friedrich

Leukemia 2017 31: 1743-1751; advance online publication, December 27, 2016; 10.1038/leu.2016.388

Abstract | Full Text


Alloreactivity: the Janus-face of hematopoietic stem cell transplantation OPEN

A Gratwohl, A Sureda, J Cornelissen, J Apperley, P Dreger, R Duarte, H T Greinix, E Mc Grath, N Kroeger, F Lanza, A Nagler, J A Snowden, D Niederwieser and R Brand for the European Society for Blood and Marrow Transplantation (EBMT)

Leukemia 2017 31: 1752-1759; advance online publication, March 8, 2017; 10.1038/leu.2017.79

Abstract | Full Text


Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

K T Siu, J Ramachandran, A J Yee, H Eda, L Santo, C Panaroni, J A Mertz, R J Sims III, M R Cooper and N Raje

Leukemia 2017 31: 1760-1769; advance online publication, November 28, 2016; 10.1038/leu.2016.355

Abstract | Full Text

Enhanced MAPK signaling is essential for CSF3R-induced leukemia

S Rohrabaugh, M Kesarwani, Z Kincaid, E Huber, J Leddonne, Z Siddiqui, Y Khalifa, K Komurov, H L Grimes and M Azam

Leukemia 2017 31: 1770-1778; advance online publication, December 27, 2016; 10.1038/leu.2016.376

Abstract | Full Text


EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia OPEN

S Charmsaz, F Al-Ejeh, T M Yeadon, K J Miller, F M Smith, B W Stringer, A S Moore, F-T Lee, L T Cooper, C Stylianou, G T Yarranton, J Woronicz, A M Scott, M Lackmann and A W Boyd

Leukemia 2017 31: 1779-1787; advance online publication, December 6, 2016; 10.1038/leu.2016.371

Abstract | Full Text

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen OPEN

S Rafiq, T J Purdon, A F Daniyan, M Koneru, T Dao, C Liu, D A Scheinberg and R J Brentjens

Leukemia 2017 31: 1788-1797; advance online publication, December 7, 2016; 10.1038/leu.2016.373

Abstract | Full Text


Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia

W S Liau, S H Tan, P C T Ngoc, C Q Wang, V Tergaonkar, H Feng, Z Gong, M Osato, A T Look and T Sanda

Leukemia 2017 31: 1798-1807; advance online publication, December 28, 2016; 10.1038/leu.2016.392

Abstract | Full Text


The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies

A Statler, T Radivoyevitch, C Siebenaller, A T Gerds, M Kalaycio, E Kodish, S Mukherjee, C Cheng and M A Sekeres

Leukemia 2017 31: 1808-1815; advance online publication, December 7, 2016; 10.1038/leu.2016.374

Abstract | Full Text

Letters to the Editor


Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma

S Knop, C Langer, M Engelhardt, L-O Mügge, A Reichle, W Rösler, F Bassermann, B Hertenstein, A Kunitz, C Röllig, H Ostermann, K Schäfer-Eckart, M Ringhoffer, A Günther, C Junghanss, H Biersack, M Schreder, A Liebert, S Held, H Einsele and R C Bargou for the Deutsche Studiengruppe Multiples Myelom (DSMM)

Leukemia 2017 31: 1816-1819; advance online publication, April 25, 2017; 10.1038/leu.2017.124

Full Text

Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster OPEN

G Cazzaniga, L Bisanti, G Randi, S Deandrea, S Bungaro, F Pregliasco, D Perotti, F Spreafico, G Masera, M G Valsecchi, A Biondi and M Greaves

Leukemia 2017 31: 1819-1821; advance online publication, April 27, 2017; 10.1038/leu.2017.127

Full Text

Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

M van der Meulen, A G Dinmohamed, O Visser, J K Doorduijn and J E C Bromberg

Leukemia 2017 31: 1822-1825; advance online publication, April 28, 2017; 10.1038/leu.2017.128

Full Text

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden OPEN

N Gunnarsson, M Höglund, L Stenke, F Sandin, M Björkholm, A Dreimane, M Lambe, B Markevärn, U Olsson-Strömberg, H Wadenvik, J Richter and A Själander

Leukemia 2017 31: 1825-1827; advance online publication, May 2, 2017; 10.1038/leu.2017.131

Full Text

Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome

J R Schwartz, S Wang, J Ma, T Lamprecht, M Walsh, G Song, S C Raimondi, G Wu, M F Walsh, R B McGee, C Kesserwan, K E Nichols, B E Cauff, R C Ribeiro, M Wlodarski and J M Klco

Leukemia 2017 31: 1827-1830; advance online publication, May 10, 2017; 10.1038/leu.2017.142

Full Text

Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

L Chen, H Mao, J Zhang, J Chu, S Devine, M A Caligiuri and J Yu

Leukemia 2017 31: 1830-1834; advance online publication, May 12, 2017; 10.1038/leu.2017.147

Full Text

A critical role of periostin in B-cell acute lymphoblastic leukemia OPEN

Z Ma, X Zhao, J Huang, X Jia, M Deng, D Cui, Z Du, G Fu, G Ouyang and C Xiao

Leukemia 2017 31: 1835-1837; advance online publication, May 22, 2017; 10.1038/leu.2017.149

Full Text

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis

J-P Defour, Y Hoade, A-M Reuther, A Callaway, D Ward, F Chen, S N Constantinescu and N C P Cross

Leukemia 2017 31: 1838-1839; advance online publication, May 22, 2017; 10.1038/leu.2017.153

Full Text

Prognostic impact of IKZF1 deletions in association with vincristine–dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95 OPEN

L Hinze, A Möricke, M Zimmermann, S Junk, G Cario, E Dagdan, C P Kratz, V Conter, M Schrappe and M Stanulla

Leukemia 2017 31: 1840-1842; advance online publication, May 22, 2017; 10.1038/leu.2017.154

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: